GATA1 and diffuse large B-cell lymphoma: Combined with the current clinical situation, it is not difficult to find that many anti-DLBCL therapeutic drugs are realized through protease inhibitors, inhibition of oxidative phosphorylation, and GATA1 is closely related to these two pathways, and we hypothesize that GATA1 can be the next therapeutic DLBCL target.